PanACEA is an African–European consortium formed in 2008 and funded by EDCTP to 2015. The consortium includes 11 African research sites in six countries, including world leading research institutions such as the Universities of Cape Town, Stellenbosch, Witwatersrand, and the Aurum Institute for Health Research in South Africa, the Ifakara Health Institute, the Mbeya Medical Research Centre, and the Kilimanjaro Clinical Research Institute in Tanzania. European partner institutions are the University of Munich (Germany), Radboud University (The Netherlands), Swiss Tropical and Public Health Institute (Switzerland), University of St. Andrews, (United Kingdom), and University College London (United Kingdom).
In the first funding period PanACEA has built new clinical trial capacity in three Tanzanian sites, has expanded TB expertise in Gabon and Uganda and conducted four phase II and one phase III fully GCP compliant, regulatory-standard TB clinical trials. PanACEA’s African partners are supported by European expertise in all aspects of tuberculosis drug development: clinical research, pharmacology, TB trial design and statistics, sponsor oversight, specialist mycobacteriology and biomarker innovation.
PanACEA’s open approach to drug developers has facilitated access to a comprehensive portfolio of new drug candidates, including Q203, BTZ043, and several ß-lactams. Through cooperation with the PreDiCT-TB consortium and the German Center for Infection Research (DZIF), PanACEA has access to modelling, and enhanced preclinical efficacy testing in standard and humanised mouse models to complement clinical trial data. Importantly, PanACEA is working with other TB trials networks beyond Europe (including the TB Alliance, the US NIH and the US CDC TBTC), to enhance coordination in development and avoid duplication. For more information on the first PanACEA programme, see also the PanACEA website.